Millions of People Will Soon Be Blindsided. Will You Be One of Them?

On April 20 at 7 p.m. ET, Louis Navellier and Matt McCall will reveal an event that’s about to rock the stock market and how you could use it to beat the markets by nearly 11X.

Tue, April 20 at 7:00PM ET

GW Pharmaceuticals Earnings: GWPH Stock Soars as Q1 Revenue Triples

GW Pharmaceuticals (NASDAQ:GWPH) announced its fiscal first-quarter’s results to begin its 2019, which included revenue that tripled when compared to the year-ago quarter, but it missed what Wall Street called for in its consensus estimate.

GW Pharmaceuticals EarningsThe United Kingdom-based biopharmaceutical company said that for its first quarter, net losses reached $71.9 million, or 20 cents per share. In the first quarter of its fiscal 2018, net losses were more than $10 million narrower at $61.8 million, or 20 cents per share.

Analysts had called for GW Pharmaceuticals to amass losses of roughly 23 cents per share for its most recent quarter, according to a FactSet survey.

The company also brought in revenue of $6.6 million, a 200% increase from the $6.6 million it garnered during the same quarter a year ago. The Wall Street guidance included a revenue projection that was higher than what analysts predicted at roughly $11.4 million, per FactSet.

GW Pharmaceuticals is now in the midst of its second quarter of the fiscal 2019, which analysts predict will include a loss of 22 cents per share. Revenue is slated to reach roughly $22 million.

The biopharmaceutical organization developed nabiximols, a product developed using the cannabis plant to treat multiple sclerosis.

GWPH stock was surging about 1.4% during regular trading hours ahead of the company’s quarterly report. Shares then surged an additional 3.9% after hours on Tuesday thanks to an increase in revenue and a loss that was narrow when compared to what analysts called for.

Article printed from InvestorPlace Media,

©2021 InvestorPlace Media, LLC